Evidence map›Paper›PMID 27965292›Full record

ArticleGenome research2017

Engineered LINE-1 retrotransposition in nondividing human neurons.

Angela Macia, Thomas J Widmann, Sara R Heras, Veronica Ayllon, Laura Sanchez, Meriem Benkaddour-Boumzaouad, Martin Muñoz-Lopez, Alejandro Rubio, Suyapa Amador-Cubero, Eva Blanco-Jimenez and 6 more

Open access · greenAbstract read
In one paragraph

Article in Genome research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 1 synthesis or guideline pooled it, 161 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. LINE-1 Retrotransposons and Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Building the brain mosaic: an expanded view.Trends in genetics : TIG · 2024
    Review
  17. Review
  18. Retrotransposons in embryogenesis and neurodevelopment.Biochemical Society transactions · 2024
    Review
  19. Article
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 3 countries.

Angela MaciaDepartment of Genomic Medicine and Centre for Genomics and Oncology (Pfizer-University of Granada and Andalusian Regional Government), PTS Granada, 18016 Granada, Spain.
Thomas J WidmannDepartment of Genomic Medicine and Centre for Genomics and Oncology (Pfizer-University of Granada and Andalusian Regional Government), PTS Granada, 18016 Granada, Spain.
Sara R HerasDepartment of Genomic Medicine and Centre for Genomics and Oncology (Pfizer-University of Granada and Andalusian Regional Government), PTS Granada, 18016 Granada, Spain.
Veronica AyllonDepartment of Oncology, GENYO, Centre for Genomics and Oncology (Pfizer-University of Granada and Andalusian Regional Government), PTS Granada, 18016 Granada, Spain.
Laura SanchezDepartment of Genomic Medicine and Centre for Genomics and Oncology (Pfizer-University of Granada and Andalusian Regional Government), PTS Granada, 18016 Granada, Spain.
Meriem Benkaddour-BoumzaouadDepartment of Genomic Medicine and Centre for Genomics and Oncology (Pfizer-University of Granada and Andalusian Regional Government), PTS Granada, 18016 Granada, Spain.
Martin Muñoz-LopezDepartment of Genomic Medicine and Centre for Genomics and Oncology (Pfizer-University of Granada and Andalusian Regional Government), PTS Granada, 18016 Granada, Spain.
Alejandro RubioDepartment of Genomic Medicine and Centre for Genomics and Oncology (Pfizer-University of Granada and Andalusian Regional Government), PTS Granada, 18016 Granada, Spain.
Suyapa Amador-CuberoDepartment of Genomic Medicine and Centre for Genomics and Oncology (Pfizer-University of Granada and Andalusian Regional Government), PTS Granada, 18016 Granada, Spain.
Eva Blanco-JimenezDepartment of Genomic Medicine and Centre for Genomics and Oncology (Pfizer-University of Granada and Andalusian Regional Government), PTS Granada, 18016 Granada, Spain.
Javier Garcia-CastroUnidad de Biotecnología Celular, ISCIII, Madrid, E-28021, Spain.
Pablo MenendezDepartment of Oncology, GENYO, Centre for Genomics and Oncology (Pfizer-University of Granada and Andalusian Regional Government), PTS Granada, 18016 Granada, Spain.
Philip NgDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030, USA.
Alysson R MuotriDepartment of Pediatrics/Rady Children's Hospital San Diego, University of California San Diego, La Jolla, California 92093, USA.
John L GoodierMcKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
Jose L Garcia-PerezDepartment of Genomic Medicine and Centre for Genomics and Oncology (Pfizer-University of Granada and Andalusian Regional Government), PTS Granada, 18016 Granada, Spain.
Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESBaylor College of Medicine · USInstitució Catalana de Recerca i Estudis Avançats · ESInstituto de Salud Carlos III · ESJohns Hopkins University · USUniversity of California San Diego · USWestern General Hospital · GB

Funding

Exploring a role for LINE1 retrotransposons in neurodegenerative diseaseR03NS087290 · NINDS · JOHNS HOPKINS UNIVERSITY · PI GOODIER, JOHN LAWRENCE · 2014 to 2015
$162k
Howard Hughes Medical Institute IECS-55007420NINDS NIH HHS R03 NS087290Wellcome Trust
6 · The paper itself

Abstract

Half the human genome is made of transposable elements (TEs), whose ongoing activity continues to impact our genome. LINE-1 (or L1) is an autonomous non-LTR retrotransposon in the human genome, comprising 17% of its genomic mass and containing an average of 80-100 active L1s per average genome that provide a source of inter-individual variation. New LINE-1 insertions are thought to accumulate mostly during human embryogenesis. Surprisingly, the activity of L1s can further impact the somatic human brain genome. However, it is currently unknown whether L1 can retrotranspose in other somatic healthy tissues or if L1 mobilization is restricted to neuronal precursor cells (NPCs) in the human brain. Here, we took advantage of an engineered L1 retrotransposition assay to analyze L1 mobilization rates in human mesenchymal (MSCs) and hematopoietic (HSCs) somatic stem cells. Notably, we have observed that L1 expression and engineered retrotransposition is much lower in both MSCs and HSCs when compared to NPCs. Remarkably, we have further demonstrated for the first time that engineered L1s can retrotranspose efficiently in mature nondividing neuronal cells. Thus, these findings suggest that the degree of somatic mosaicism and the impact of L1 retrotransposition in the human brain is likely much higher than previously thought.

Indexed as

DNA Transposable ElementsLong Interspersed Nucleotide ElementsCell DivisionCells, CulturedHeLa CellsHematopoietic Stem CellsHumansMesenchymal Stem CellsMosaicismNeural Stem CellsDNA Transposable Elements

Identifiers

PMID27965292
PMCPMC5340962
OpenAlexW2566189817

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.